From the Outside Looking in: Psoriasiform Dermatitis Presenting as a Paraneoplastic Syndrome for Pancreatic Adenocarcinoma

Narasimha, Shruthi; Shah, Jessica; Drame, Awa

doi:10.7759/cureus.9067

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, distinguishing between psoriasis and AD, especially when clinical and histological findings overlap, can be challenging (2). In such cases, the term "psoriasiform dermatitis" is employed to describe variable eczema-like histopathological changes with a psoriasiform appearance (3)(4)(5). Histologic features overlapping with psoriasis include edema of the papillary dermis and the presence of Munro microabscesses, while ADassociated features encompass neutrophil and plasma exudation in parakeratosis, lymphocytic exocytosis in the epidermis, fullthickness spongiosis, or spongiotic vesicle formation.…”

Section: Discussionmentioning

confidence: 99%

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Mao,

Du,

Jia

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Psoriasis and atopic dermatitis (AD) are prevalent inflammatory skin disorders, each stemming from diverse factors, and characterized by recurring episodes. In certain complex cases, the clinical and pathological features exhibit overlapping and atypical characteristics, making accurate clinical diagnosis and targeted treatment a challenge. Psoriasiform dermatitis is the term used to describe such cases. Moreover, when patients have a history of malignancy, the situation becomes even more intricate, resulting in limited treatment options. Biologic therapies have transformed the management of immune-mediated inflammatory diseases, including psoriasis and AD. Meanwhile, the safety of biologics in special populations, especially among patients with a history of malignancy, should be underlined. The selective Janus kinase 1 (JAK1) inhibitor abrocitinib has been approved for the treatment of AD and has showed satisfying efficacy and safety in the treatment of psoriasis in clinical trials. Although unreported, JAK1 inhibitors are thought to have the potential to increase the risk of potential tumors. Apremilast, an oral phosphodiesterase (PDE)-4 inhibitor, is approved for moderate to severe plaque psoriasis. It has been investigated for its efficacy in AD, and is not contraindicated in malignancy. This report presents three cases of psoriasiform dermatitis in patients with a history of malignancy, showcasing significant improvement following treatment with systemic glucocorticoid, abrocitinib, or apremilast.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Mao,

Du,

Jia

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Bazex Syndrome (Acrokeratosis Paraneoplastica): A Narrative Review of Pathogenesis, Clinical Manifestations, and Therapeutic Approaches

Shah,

Ferrazzano,

Karthikeyan

et al. 2023

Cureus

View full text Add to dashboard Cite

Acrokeratosis paraneoplastica, also known as Bazex syndrome, is a relatively understudied yet clinically important dermatological condition that is inextricably associated with squamous cell carcinoma, predominantly of the upper respiratory and gastrointestinal tracts. Manifesting as unique psoriasis-like cutaneous lesions, Bazex syndrome functions as an early warning signal for underlying malignancies, underscoring the urgent need for its timely diagnosis and intervention. Notwithstanding its clinical relevance, the molecular and cellular mechanisms underpinning its pathogenesis are not fully understood. To address these gaps, this comprehensive literature review undertook a meticulous search across reputable databases such as EMBASE, MEDLINE/PubMed, and Web of Science. Our analysis ventures into multiple putative pathogenic pathways, including shifts in Th2 immune responses, aberrant secretion of growth factors, and immunological reactions to tumor-specific antigens. We also detail the clinical phenotypes of Bazex syndrome and their chronological linkage with the corresponding malignancies. Finally, the review evaluates the therapeutic effectiveness of various approaches, including but not limited to targeted cancer treatments, PUVA therapy, and topical corticosteroids. This synthesis aims to arm healthcare providers with a nuanced understanding of Bazex syndrome, facilitating more accurate diagnosis and tailored treatment paradigms.

show abstract

From the Outside Looking in: Psoriasiform Dermatitis Presenting as a Paraneoplastic Syndrome for Pancreatic Adenocarcinoma

Cited by 2 publications

References 3 publications

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Bazex Syndrome (Acrokeratosis Paraneoplastica): A Narrative Review of Pathogenesis, Clinical Manifestations, and Therapeutic Approaches

Contact Info

Product

Resources

About